© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Brain Changes, Weight Management, and Breast Screening: Essential Updates From TMS 2025
October 30, 2025
New research from TMS 2025 covers menopause effects on brain volume, hormone therapy's role in weight loss with GLP-1s, and dense breast screening updates.
7 Drugs Approved for Primary Care: Q3 2025
October 29, 2025
Catch up on the 7 FDA drug approvals from Q3 2025 most relevant to primary care, including new treatments for cardiometabolic, infectious disease, and inflammatory diseases.
When Should Mammography Begin? Donna Plecha, MD, on Differing Breast Cancer Screening Guidelines
October 29, 2025
Early breast cancer screening at age 40, especially with 3D mammograms, significantly improves survival rates and quality of life, according to Dr Plecha.
Community Factors Show Distinct Patterns Across Cancer Types in Nationwide Analysis
October 29, 2025
Smoking drives lung cancer deaths, but race predicts breast/prostate mortality. New study reveals distinct community factors for each cancer type's outcomes.
FAQs On The Critical Window Hypothesis for Menopausal Hormone Therapy's Neuroprotective Effects
October 29, 2025
Common questions on the critical window hypothesis for timing of postmenopausal MHT ask about rationale, clinical evidence, and guideline response.
MHT and Alzheimer Risk: New Evidence for a Critical Window, with Roksana Karim, MD, PhD
October 29, 2025
Karim discusses secondary findings from the ELITE trial of timing for estradiol initiation, which reveal a notable impact on Aβ biomarkers of Alzheimer disease.
Xuezhi Daniel Jiang, MD, PhD, on Counseling Postmenopausal Women on Autoimmune Disease Risk Without Creating Hormone Therapy Phobia
October 28, 2025
Jiang shares how to use new autoimmune risk data responsibly—identifying high-risk patients while avoiding unnecessary hormone therapy phobia.
Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial
October 28, 2025
The phase 3 DREAMS-3 trial is the fist phase 3 head-to-head comparison of a GLP-1/glucagon dual receptor agonist against semaglutide in diabetes treatment.
Hormone Therapy Linked to Increased Autoimmune Disease Risk
October 28, 2025
Dr. Daniel Jiang shares unexpected research findings showing hormone therapy increased autoimmune disease risk across 15 of 17 conditions in postmenopausal women.
Investigational Oral Agent ALZ-801 Slows Brain Atrophy and Cognitive Decline in APOE4 Homozygotes with Early AD
October 28, 2025
Valiltramiprosate is a novel disease modifying therapy designed to inhibit formation of soluble neurotoxic amyloid oligomers, acting upstream in the amyloid cascade.